Products
Gavilimomab Biosimilar Monoclonal Antibody (CD147) for Research
Cat No.: GMP-Bios-INN-853
Anti-BSG therapeutic antibody (Pre-made Gavilimomab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2]
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-853-1mg | 1mg | 3090 |
| GMP-Bios-INN-853-10mg | 10mg | |
| GMP-Bios-INN-853-100mg | 100mg | |
| GMP-Bios-INN-853-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Gavilimomab Biosimilar, Whole Mab, Anti-Bsg Antibody: Anti-5F7/CD147/EMMPRIN/EMPRIN/HAb18G/OK/TCSF therapeutic antibody |
| INN Name | Gavilimomab |
| Target | BSG |
| Format | Whole mAb |
| Derivation | Mus musculus |
| Species Reactivity | human |
| CH1 Isotype | IgM - nd |
| VD LC | IgM - nd |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Abgenix (Fremont CA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
